Use of COMT inhibitors for the manufacture of a medicament...

Details Use of COMT inhibitors for the manufacture of a medicament... Use of COMT inhibitors for the manufacture of a medicament...

1999-08-23

2001-03-27

Weddington, Kevin E. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S520000

Reexamination Certificate

active

06207706

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to the use of catechol-O-methyl transferase (COMT) inhibitors in the prevention of diabetic vascular dysfunctions, preferably nephropathy, retinopathy and neuropathy.
BACKGROUND OF THE INVENTION
There is a world-wide search for a therapy that can prevent the complications in type 1 and type 2 diabetes. Chronic exposure to diabetes leads to an increased incidence of microangiopathic complications which are associated with considerable morbidity and mortality. For example, disturbances in the microcirculation of the feet may lead to amputation of the legs which in turn can cause severe complications. In the case of diabetic nephropathy renal failure is usually the actual cause of death. Diabetes is also the most common cause of renal failure among young adults.
The factors that lead to diabetic nephropathy have been extensively studied but are still incompletely known. According to the general concept, early functional effects of diabetes, such as hyperfiltration, are contributing factors. Hyperfiltration is associated with increased glomerular pressure and increased albumin excretion rate (AER). Increased AER is considered to be an early sign of glomerular damage.
The presently most commonly used therapy, ACE inhibitors, will not prevent the development of diabetic nephropathy, but may postpone the development of terminal renal failure.
It has been disclosed that nitecapone, a COMT inhibitor has a natriuretic effect (Eklöf et al. J. Am. Soc. Nephrology 5 (3), 657, 1994, Holtbäck et al., J. Am. Soc. Nephrology, 7(9), 1633, 1996). However, the effect of COMT inhibitors on hyperfiltration and albuminuria has not been suggested earlier.
SUMMARY OF THE INVENTION
The object of the invention is to provide the use of COMT inhibitors, especially nitecapone (3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione) in the the prevention of diabetic vascular dysfunctions, such as nephropathy, retinopathy and neuropathy. The compounds of the invention may be used for the treatment of any type of diabetes.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Suitable COMT-inhibitors and methods for preparation thereof have been described, e.g. in GB 2200109, EP 237929 and PCT application PCT/FI96/00295.
The invention is directed to the use of COMT inhibitors or their pharmaceutically acceptable salts or esters in the manufacture of a medicament for use in the prevention of diabetic vascular dysfunctions, such as the prevention of dysfunctions related to microangiopathy; nephropathy and/or retinopathy; and the attenuation of albuminuria. A COMT inhibitor useful in this regard is nitecapone.
The invention is also directed to a method for the prevention of diabetic vascular dysfunctions by administering to a mammal in need of such prevention an effective amount of a COMT inhibitor or its pharmaceutically acceptable salt or ester to prevent said dysfunctions, such as the prevention of a dysfunction related to microangiopathy; nephropathy and/or retinopathy. A COMT inhibitor useful in this regard is nitecapone.
Pharmaceutically acceptable salts and esters of these compounds, when applicable, may be prepared by known methods. All physiologically acceptable salts are useful as active medicaments, however, sodium, potassium, ammonium, calcium and magnesium salts and salts with hydrochloric, hydrobromic, phosphoric and sulfuric acids and with organic acids like oxalic, fumaric, tartaric, malonic, acetic and citric acids etc. are preferred.
The effective dose of the compound varies considerably depending on the efficacy of the COMT-inhibitor in question, the severity of the condition to be treated, and the route of administration. Most preferred are oral formulations. The effective dose for human beings is likely to be from about 20 to 2000 mg per day.
The compounds according to this invention are given to a patient as such or in combination with one or more other active ingredients and/or suitable pharmaceutical non-active additives. The latter group comprises solvents, gel forming agents, emulsifiers, stabilizers, colorants, preservatives, lubricants, glidants, fillers and other widely used excipients and formulation aids.
The compounds used in this invention are formulated into dosage forms using commonly known pharmaceutical manufacturing methods. The dosage forms can be e.g. tablets, capsules, granules, suppositories, emulsions, suspensions or solutions. Depending on the route of administration and the galenic form, the concentration of the active compound in a formulation can typically vary between about 1 to 100 % (w/w).
Choosing the auxiliary ingredients for the formulation is routine for those of ordinary skill in the art. It is evident that suitable solvents, gel forming ingredients, dispersion forming ingredients, colors etc. are used in a normal way.


REFERENCES:
patent: 4672042 (1987-06-01), Ross, Jr. et al.
patent: 4963590 (1990-10-01), Bäckström et al.
patent: 5001152 (1991-03-01), Aho et al.
patent: 5019575 (1991-05-01), Haikala et al.
patent: 5112861 (1992-05-01), Bäckström et al.
patent: 5122524 (1992-06-01), Haikala et al.
patent: 5185332 (1993-02-01), Haikala et al.
patent: 5185370 (1993-02-01), Bäckström et al.
patent: 5236952 (1993-08-01), Bernauer et al.
patent: 5283352 (1994-02-01), Bäckström et al.
patent: 5288750 (1994-02-01), Pohto et al.
patent: 5292771 (1994-03-01), Bäckström et al.
patent: 5389653 (1995-02-01), Bernauer et al.
patent: 5446194 (1995-08-01), Backstrom et al.
patent: 5476875 (1995-12-01), Bernauer et al.
patent: 5489614 (1996-02-01), Korkolainen et al.
patent: 0 237 929 A1 (1987-09-01), None
patent: 2 200 109 (1988-07-01), None
patent: WO 96/37456 (1996-11-01), None
Eklöf, A.-C. et al., “Natriuretic and Vasodilating Effects of Dopamine are Mimicked by Oral Administration of a Catechol-O-Methyltransferase (COMT) Inhibitor,”J. Am. Soc. Nephrology5:657, Abstract No. 23P (Oct., 1994).
Holtbäck, U. et al., “Regulators of Renal Dopamine Metabolism Control Salt Excretion,”J. Am. Soc. Nephrology7:1633, Abstract A1922 (Nov., 1996).
Kaakkola, S. et al., “General Properties and Clinical Possibilities of New Selective Inhibitors of Catechol O-methyltransferase,”Gen. Pharmac.25:813-824 (Sep., 1994).
Dialog File 351, Derwent WPI English language abstract for EP 0 237 929 (Doc. AL1).

Affiliated with

Also associated with

Rating

Use of COMT inhibitors for the manufacture of a medicament... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of COMT inhibitors for the manufacture of a medicament..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of COMT inhibitors for the manufacture of a medicament... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2522276